24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
APRELIEVA 125MG is an Capsule medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | APRELIEVA 125MG |
|---|---|
| Composition | Aprepitant Capsules IP 125mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsule |
| Packaging | KIT |
| Country of Origin | India |
Aprepitant Capsules IP 125mg (Aprepitant Capsules IP 125mg) is a widely used Capsule medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
APRELIEVA 125 MG (Aprepitant Capsules IP 125 mg) is an antiemetic medicine used to help prevent nausea and vomiting caused by chemotherapy treatment and certain medical procedures. It contains Aprepitant, a neurokinin-1 (NK1) receptor antagonist that works by blocking specific signals in the brain responsible for triggering nausea and vomiting.
Cancer patients undergoing chemotherapy often experience severe nausea and vomiting as side effects of anticancer treatment. These symptoms can affect overall health, appetite, energy levels, and quality of life. APRELIEVA 125 MG is specially formulated to help reduce chemotherapy-induced nausea and vomiting (CINV), making cancer treatment more manageable and comfortable for patients.
Aprepitant works differently from traditional anti-nausea medicines. It targets substance P, a natural chemical in the brain associated with the vomiting reflex. By blocking NK1 receptors, APRELIEVA helps prevent both acute and delayed nausea and vomiting that may occur during or after chemotherapy sessions.
This medicine is commonly prescribed along with other antiemetic medicines such as:
• Ondansetron
• Dexamethasone
• Other supportive cancer care medicines
APRELIEVA 125 MG is widely used in:
• Chemotherapy-induced nausea prevention
• Delayed vomiting prevention after chemotherapy
• Supportive oncology care
• Cancer treatment management programs
• Certain surgery-related nausea prevention protocols under medical supervision
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. APRELIEVA should only be used under the guidance of qualified healthcare professionals.
Doctors may prescribe this medicine before chemotherapy sessions to help improve patient comfort and treatment tolerance. Effective nausea management is important because uncontrolled vomiting may lead to dehydration, weakness, nutritional problems, and difficulty continuing cancer treatment.
Patients using APRELIEVA 125 MG may require individualized dosing schedules depending on the type of chemotherapy, severity of symptoms, and overall treatment plan. Proper medical supervision helps improve treatment effectiveness and reduce complications.
Due to its effectiveness in supportive oncology care and chemotherapy-related symptom management, APRELIEVA 125 MG has become an important medicine in modern cancer care protocols.
APRELIEVA 125 MG (Aprepitant Capsules IP 125 mg) is mainly used for the prevention and management of nausea and vomiting associated with chemotherapy and certain medical conditions.
APRELIEVA is widely used to prevent nausea and vomiting caused by chemotherapy treatment.
The medicine helps reduce delayed nausea and vomiting that may occur after chemotherapy sessions.
Doctors commonly prescribe Aprepitant as part of supportive cancer care treatment protocols.
APRELIEVA is often used along with other anti-nausea medicines for improved symptom control.
The medicine helps improve patient comfort and supports better chemotherapy tolerance.
In some cases, doctors may prescribe Aprepitant to help prevent nausea and vomiting after surgery under medical supervision.
Aprepitant belongs to a class of medicines known as NK1 receptor antagonists.
APRELIEVA works by:
• Blocking neurokinin-1 (NK1) receptors
• Preventing substance P from triggering vomiting signals
• Reducing nausea sensation
• Helping control chemotherapy-related vomiting
• Supporting better cancer treatment tolerance
This targeted mechanism helps improve nausea management during chemotherapy treatment.
Like other medicines, APRELIEVA 125 MG may cause side effects in some patients. Side effects may vary depending on the patient’s health condition, chemotherapy type, and response to treatment.
Patients may experience tiredness or reduced energy levels.
Mild to moderate headaches may occur during treatment.
Digestive changes such as constipation may develop in some patients.
Certain individuals may experience loose stools or digestive discomfort.
Some patients may feel dizzy or lightheaded.
Reduced appetite may occur during chemotherapy and supportive treatment.
Hiccups are occasionally reported with Aprepitant therapy.
Mild abdominal discomfort or stomach pain may occur.
Difficulty sleeping or changes in sleep pattern may occasionally develop.
Some serious side effects may require immediate medical attention.
• Severe allergic reactions
• Difficulty breathing
• Swelling of face or throat
• Severe skin reactions
• Persistent dizziness
• Severe weakness
• Chest pain
• Unusual symptoms after chemotherapy
Patients should contact their healthcare provider immediately if severe symptoms occur.
The dosage of APRELIEVA 125 MG (Aprepitant Capsules IP 125 mg) should always be determined by a qualified healthcare professional based on the patient’s chemotherapy regimen and medical condition.
Different chemotherapy medicines may require different antiemetic dosing schedules.
Patients receiving highly emetogenic chemotherapy may require specific dosing protocols.
APRELIEVA is often used along with other anti-nausea medicines, which may affect dosage planning.
The patient’s liver function and general health may influence dosage adjustments.
Doctors may modify the treatment plan depending on symptom control and side effects.
• Take the capsule exactly as prescribed
• Swallow the capsule whole with water
• Usually taken before chemotherapy sessions
• Follow the prescribed treatment schedule carefully
• Do not change dosage without medical advice
Patients should always follow their doctor’s instructions for chemotherapy supportive care.
Before starting treatment, patients should inform their doctor if they have:
• Liver disease
• Allergic reactions to medicines
• Heart-related conditions
• Ongoing chemotherapy complications
• Other chronic medical conditions
Patients should also discuss all ongoing medicines and supplements because Aprepitant may interact with certain drugs.
Pregnant or breastfeeding women should use this medicine only if recommended by a healthcare professional.
• Store in a cool and dry place
• Protect from moisture and sunlight
• Keep out of reach of children
• Store at recommended room temperature
• Effective chemotherapy nausea prevention
• Trusted supportive oncology care medicine
• Advanced NK1 receptor antagonist formulation
• Reliable antiemetic treatment support
• Manufactured under strict pharmaceutical standards
• Suitable for modern cancer care protocols
It is mainly used to prevent nausea and vomiting caused by chemotherapy treatment.
Aprepitant is an antiemetic medicine that blocks NK1 receptors to help control nausea and vomiting.
Yes, it is commonly prescribed before chemotherapy sessions to reduce treatment-related nausea and vomiting.
No, it is a supportive care medicine used to manage chemotherapy side effects.
Yes, some patients may experience dizziness or fatigue during treatment.
Yes, patients should use this medicine under the supervision of qualified healthcare professionals.
Doctors often prescribe it along with other antiemetic medicines for better symptom control.
No, patients should always follow the treatment schedule recommended by their doctor.